Elsevier

European Journal of Pharmacology

Volume 168, Issue 3, 22 September 1989, Pages 291-298
European Journal of Pharmacology

Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists

https://doi.org/10.1016/0014-2999(89)90790-5Get rights and content

Abstract

The effects of continuous and intermittent levodopa treatment on rotational behavior induced by dopamine agonists were examined in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal dopamine pathway. Chronic administration of levodopa by continuous infusion (90–100 mg/kg per day i.p. by osmotic pump for 19 days with a 3 day washout) enhanced the rotational response to the D-2 dopamine receptor agonist quinpirole, but had no effect on rotation induced by the D-1 agonist SKF 38393 or that due to the non-selective dopamine agonist apomorphine. The rotational responses to the selective dopamine agonists differed dramatically in rats treated with levodopa by intermittent injection (45–50 mg/kg i.p., b.i.d. for 19 days with a 3 day washout): they showed a markedly increased response to quinpirole, a greatly diminished response to SKF 38393, and a modestly enhanced response to apomorphine. Continuous and intermittent treatment resulted in equivalent daily plasma levodopa levels. These findings suggest that the intermittence of central dopamine receptor stimulation may be an important factor in determining the subsequent responses of the dopamine system. The dissociation between the effects of both continuous and intermittent levodopa on D-1 and D-2 agonist-induced rotation indicates that D-1 and D-2 dopamine receptor-mediated mechanisms respond differently to chronic levodopa treatment.

References (16)

There are more references available in the full text version of this article.

Cited by (147)

  • Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies

    2021, Brain Research Bulletin
    Citation Excerpt :

    In rats, stereotactic injection of 6-OHDA in the nigrostriatal region causes degeneration of dopaminergic neurons and induction of PD via oxidative stress and mitochondrial respiratory chain arrest (Duty and Jenner, 2011). In addition, to induce levodopa induced dyskinesia or ‘wearing off’ effects, MPTP model in primates and 6-OHDA model in rats are used (Duty and Brotchie, 1997; Engber et al., 1989; Johnston and Fox, 2014). In MPTP treated C57BL/6 mice, safinamide (20 mg/kg, i.p.) when co-administrated with levodopa and benserazide, increased the brain dopamine level by 60 % (Caccia et al., 2006).

  • Banana (Musa spp) from peel to pulp: Ethnopharmacology, source of bioactive compounds and its relevance for human health

    2015, Journal of Ethnopharmacology
    Citation Excerpt :

    According to Obeso et al. (2000), a constant firing rate of CNS dopamine neurons, stable striatal dopamine concentration, and the continuos activation of striatal dopamine receptors are essential for normal basal-ganglia function (Bédard et al., 1986; Grondin et al., 1996; Jenner, 2000). Engber et al. (1989), Juncos et al. (1989), Morissette et al. (1997), and Pavon et al. (2006) findings demonstrated that standard doses of levodopa are unable to restore basal-ganglia physiological activity to normal, because non-physiological discontinuous or pulsatile dopamine replacement induces disruption in the dopamine-denervated basal ganglia leading to the development of motor complications and dyskinesia characteristic from PD. Also disease severity can influence the risk that a drug will induce pulsatile stimulation and motor complications (Bédard et al., 1986; Pearce et al., 1998).

  • Controlled iontophoretic delivery of pramipexole: Electrotransport kinetics in vitro and in vivo

    2014, European Journal of Pharmaceutics and Biopharmaceutics
    Citation Excerpt :

    It is available in the form of immediate release and extended release tablets with dose typically initiated at 0.25 mg and gradually titrated to 1.5 mg thrice daily for the immediate release formulation. The majority of the side effects associated with PD therapy have been attributed to pulsatile stimulation of the dopamine receptors [8,9]. Transdermal administration with a steady zero-order drug input eliminates peak-trough variations and enables continuous stimulation of dopamine receptors – mimicking normal physiological conditions in healthy individuals – and so reduces these complications [10,11].

View all citing articles on Scopus
View full text